Freestone Grove Partners LP Invests $535,000 in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Freestone Grove Partners LP bought a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 5,981 shares of the medical equipment provider's stock, valued at approximately $535,000.

Several other large investors also recently modified their holdings of LNTH. T. Rowe Price Investment Management Inc. grew its stake in Lantheus by 40.5% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider's stock worth $135,025,000 after buying an additional 435,445 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of Lantheus during the 4th quarter worth $36,183,000. Swedbank AB boosted its stake in Lantheus by 53.3% in the fourth quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider's stock valued at $99,054,000 after buying an additional 385,000 shares in the last quarter. Keybank National Association OH bought a new position in shares of Lantheus in the fourth quarter worth about $27,526,000. Finally, Norges Bank acquired a new stake in shares of Lantheus in the 4th quarter valued at approximately $26,189,000. 99.06% of the stock is owned by institutional investors and hedge funds.

Lantheus Stock Performance

Shares of NASDAQ LNTH traded up $0.45 during midday trading on Friday, hitting $80.89. 655,338 shares of the stock traded hands, compared to its average volume of 963,023. Lantheus Holdings, Inc. has a one year low of $74.34 and a one year high of $126.89. The business has a 50 day moving average price of $99.90 and a two-hundred day moving average price of $94.57. The company has a market cap of $5.54 billion, a PE ratio of 13.46 and a beta of 0.23.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). The company had revenue of $372.76 million for the quarter, compared to analyst estimates of $377.37 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. Lantheus's revenue for the quarter was up .8% on a year-over-year basis. During the same quarter last year, the firm posted $1.69 EPS. As a group, equities research analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Analysts Set New Price Targets

LNTH has been the subject of a number of research reports. Truist Financial dropped their price target on Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a research note on Thursday. JMP Securities reissued a "market outperform" rating and set a $112.00 target price on shares of Lantheus in a report on Tuesday, January 14th. B. Riley cut their price target on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a report on Friday, March 21st. Finally, StockNews.com upgraded Lantheus from a "hold" rating to a "buy" rating in a report on Thursday. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of "Buy" and an average price target of $132.67.

Insider Buying and Selling

In related news, CFO Robert J. Jr. Marshall sold 10,000 shares of the stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the completion of the transaction, the chief financial officer now owns 113,860 shares in the company, valued at approximately $11,445,207.20. This represents a 8.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Mary Anne Heino sold 53,107 shares of the stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the transaction, the director now directly owns 440,399 shares of the company's stock, valued at $41,551,645.65. This represents a 10.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 63,109 shares of company stock worth $6,016,046. 2.00% of the stock is owned by insiders.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.